Abstracts tagged "clinical practice and treatment"

Abstract Number: 769 • 2016 ACR/ARHP Annual Meeting
Response to Belimumab in SLE Patients with High Disease Activity: Data from a Multicentric Clinical-Practice Based Study Cohort
Luca Iaccarino¹, Silvano Bettio², Rossella Reggia³, Giacomo Emmi⁴, Fulvia Ceccarelli⁵, Chiara Tani⁶, Maria Gerosa⁷, Marcello Govoni⁸, Alesandra Bortoluzzi⁹, Salvatore De Vita¹⁰, Ginevra De Marchi¹¹, Rossella De Angelis¹², Andrea Di Matteo¹², Carlo Salvarani¹³, Giulia Pazzola¹³, Elena Bartoloni-Bocci¹⁴, Laura Andreoli¹⁵, Margherita Zen¹⁶, Fabrizio Conti¹⁷, Marta Mosca⁶, Pier Luigi Meroni¹⁸, Roberto Gerli¹⁴, Angela Tincani¹⁹, Andrea Doria²⁰ and Lorenzo Emmi²¹, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Rheumatology Unit, Univeristy of Padova, Padova, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Medical Pathology, Careggi University Hospital, Firenze, Italy, ⁵Sapienza University of Rome, Rome, Italy, ⁶Rheumatology Unit, University of Pisa, Pisa, Italy, ⁷University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁸Medical Sciences, UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ⁹UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ¹⁰Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, ¹¹Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ¹²Polytechnic university of Marche, Rheumatologic Clinic, Iesi, Italy, ¹³Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ¹⁴Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁵University of Brescia, Spedali Civili, Brescia, Italy, ¹⁶Division of Rheumatology, University of Padova, Padova, Italy, ¹⁷Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ¹⁸Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ¹⁹Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy, ²⁰Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²¹Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic,, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy
Background/Purpose: To investigate effectiveness and identify predictors of response to belimumab in patients with active SLE in clinical practice setting. Methods: One hundred eighty eight…
Abstract Number: 2381 • 2014 ACR/ARHP Annual Meeting
Adherence to a Treat-to-Target (T2T) Strategy in Early Rheumatoid Arthritis. Is It Feasible in Daily Clinical Practice?
Christian A. Waimann¹, Gustavo Citera², Fernando Dal Pra³, Maria Celeste Orozco⁴, Federico Ceccatto⁵, Sergio Paira⁶, M Gauna⁷, Anastasia Secco⁷, M Mamani⁷, Lucila Marino⁸, Francisco Caeiro⁹, AC Alvarez¹⁰, Maria Haye Salinas⁹, L Encinas¹¹, Javier Rosa¹², Valeria Scaglioni¹³, Enrique R. Soriano¹⁴, Josefina Marcos¹⁵, Mercedes García¹⁵, A Salas¹⁵, Alejandro Martinez¹⁶, Rafael Chaparro del Moral¹⁷, Oscar Luis Rillo¹⁷, Horacio Berman¹⁸, Alberto Berman¹⁸, Francisco Colombres¹⁸, Edson Veloso¹⁹, Ricardo V. Juárez²⁰, Maria Elena Crespo²¹, Ana Quinteros²², M Leal²², Gabriela Salvatierra²³, C Ledesma²³, Mónica P. Sacnun²⁴, R Quintana²⁵ and Marcelo Abdala²⁶, ¹Rheumatology, Hospital Olavarria, Olavarria, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁴Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Rheumatology, Hospital Jose María Cullen, Santa Fé, Argentina, ⁶Section of Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁷Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁸Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁹Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ¹⁰Hospital Privado Centro Médico de, Córdoba, Argentina, ¹¹Rheumatology, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina, ¹²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹³Rheumatology Unit, Internal Medical Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁵HIGA San Martín, La Plata, Argentina, ¹⁶Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁷Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁸Centro Medico Privado de Reumatologia, Tucumán, Argentina, ¹⁹Sanatorio y Universidad Adventista Del Plata, Entre Rios, Argentina, ²⁰Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ²¹Hospital Señor Del Milagro, Salta, Argentina, ²²Centro Integral de Reumatología, Tucumán, Argentina, ²³Instituto Provincial De Rehabilitación Integral, Stgo. del Estero, Argentina, ²⁴Hospital Provincial, Rosario, Argentina, ²⁵Hospital provincial, Rosario, Argentina, ²⁶Hospital Provincial del Centenario, Santa Fe, Argentina
Background/Purpose : The treat-to-target (T2T) strategy has become the new paradigm for the treatment of Rheumatoid Arthritis (RA); however the question is whether this strategy…
Abstract Number: 668 • 2014 ACR/ARHP Annual Meeting
Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings
Josefina Cortes¹, Carlos Marras², Jose Luis Andreu³, Jaime Calvo-Alen⁴, Angel M. Garcia-Aparicio⁵, Elvira Diez Alvarez⁶, Carlos Coronell⁷, Elena Morejon⁷, Alessandra Perna⁸, Volker Koscielny⁸ and Josep Ordi-Ros¹, ¹Internal Medicine, Vall d´Hebron Hospital, Barcelona, Spain, ²Rheumatology, Virgen de la Arrixaca Hospital, Murcia, Spain, ³Rheumatology, Puerta de Hierro Universitary Hospital, Madrid, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ⁶Rheumatology, Leon Hospital, Leon, Spain, ⁷Medical Department, GlaxoSmithKline, Madrid, Spain, ⁸Medical Department, GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose After the approval of belimumab for patients with systemic lupus erythematosus (SLE), the objective of this study is to describe the clinical outcomes associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].